Matches in Wikidata for { <http://www.wikidata.org/entity/Q91036747> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q91036747 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91036747 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91036747 description "scientific article published on 01 August 2018" @default.
- Q91036747 description "wetenschappelijk artikel" @default.
- Q91036747 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91036747 name "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 name "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 type Item @default.
- Q91036747 label "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 label "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 prefLabel "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 prefLabel "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 P1433 Q91036747-BA1D6FA3-516D-43E7-B058-2AFE161CFEAA @default.
- Q91036747 P1476 Q91036747-C011C620-292F-44C5-9D3B-3E93852BD430 @default.
- Q91036747 P2093 Q91036747-1024D293-F7B0-42E4-A433-EE5EC4620074 @default.
- Q91036747 P2093 Q91036747-69D0983B-9E2B-464A-B9FE-5E6A71A37FF8 @default.
- Q91036747 P2093 Q91036747-8AF16824-EE30-42A1-B9BB-29272368823E @default.
- Q91036747 P2093 Q91036747-9AE0434B-F072-41AD-B809-71423FB7FEBF @default.
- Q91036747 P2093 Q91036747-A218AE85-8512-41D9-A3E4-B20BF411D081 @default.
- Q91036747 P2093 Q91036747-E219E37A-C089-4174-A1B9-093B361F7DFC @default.
- Q91036747 P304 Q91036747-E6F71264-0BBE-41EB-8A4F-98F74C4F9D99 @default.
- Q91036747 P31 Q91036747-D848178D-6004-4022-B4B0-84A335056D2A @default.
- Q91036747 P433 Q91036747-CAAAE577-A8AC-4576-BB2D-673CC33D8E76 @default.
- Q91036747 P478 Q91036747-742E2D58-E9BA-4BB6-AF84-FE7551823905 @default.
- Q91036747 P50 Q91036747-000E2ED2-0E66-4CB3-897D-4F0CEC6D47A0 @default.
- Q91036747 P50 Q91036747-54A4F4FD-553E-41A3-8E73-236D1C52141E @default.
- Q91036747 P577 Q91036747-19106265-68D5-4F7B-AAB6-C0E87F6847B7 @default.
- Q91036747 P698 Q91036747-ACCFC6B0-6CE8-4211-9637-4686D7E1FCDD @default.
- Q91036747 P921 Q91036747-3EF7AE67-7A84-440D-AAD7-57F88863D225 @default.
- Q91036747 P698 30124721 @default.
- Q91036747 P1433 Q25380091 @default.
- Q91036747 P1476 "Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years" @default.
- Q91036747 P2093 "Bruce Randazzo" @default.
- Q91036747 P2093 "Christopher E M Griffiths" @default.
- Q91036747 P2093 "Kim A Papp" @default.
- Q91036747 P2093 "Michael Song" @default.
- Q91036747 P2093 "Shu Li" @default.
- Q91036747 P2093 "Yaung-Kaung Shen" @default.
- Q91036747 P304 "826-832" @default.
- Q91036747 P31 Q13442814 @default.
- Q91036747 P433 "8" @default.
- Q91036747 P478 "17" @default.
- Q91036747 P50 Q57038615 @default.
- Q91036747 P50 Q64257169 @default.
- Q91036747 P577 "2018-08-01T00:00:00Z" @default.
- Q91036747 P698 "30124721" @default.
- Q91036747 P921 Q42824827 @default.